<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967249</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 766720-CS3</org_study_id>
    <secondary_id>2019-000591-42</secondary_id>
    <nct_id>NCT03967249</nct_id>
  </id_info>
  <brief_title>Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands</brief_title>
  <official_title>An Open-Label Extension Trial of IONIS GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor Administered Monthly Subcutaneously to Patients With Acromegaly Being Treated With Long-Acting Somatostatin Receptor Ligands (SRL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS
      GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL)
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This extension study will include participants up to 60 participants with acromegaly from
      Study NCT03548415. All participants will remain on the same dose from the previous study and
      receive IONIS GHR-LRx (SC) injection once every 28 days as add-on to SRL therapy for 53
      weeks. At the end of 53 weeks, participants will enter a 14-week post-treatment (PT)
      evaluation period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Adverse Events</measure>
    <time_frame>Up to approximately 16 months</time_frame>
    <description>Incidence of adverse events (AEs), serious AEs, treatment related AEs, AEs leading to withdrawal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baselines in Insulin-like Growth Factor I (IGF-1) Levels</measure>
    <time_frame>Baseline and at Week 26 and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.2 Times of Gender and Age-Adjusted Upper Limits</measure>
    <time_frame>Week 26 and at 28 days after the Week 53 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.0 Times of Gender and Age-Adjusted Upper Limits</measure>
    <time_frame>Week 26 and at 28 days after the Week 53 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Begin Other Acromegaly Medication</measure>
    <time_frame>Up to approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From First Dose of IONIS GHR-LRx in this open label extension (CS3) to Date of Initiation of Other Acromegaly Medications</measure>
    <time_frame>Up to approximately 16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>IONIS GHR-LRx + SRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS GHR-LRx</intervention_name>
    <description>IONIS GHR-LRx subcutaneous injection</description>
    <arm_group_label>IONIS GHR-LRx + SRL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRL</intervention_name>
    <description>Participants will receive SRL once monthly</description>
    <arm_group_label>IONIS GHR-LRx + SRL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomized in index trial (CS2) and completed the entire study, or completion of the
             treatment period for CS2 and completed or plan to complete PTWK5 visit with an
             acceptable safety profile, per investigator judgment

          -  Participants with confirmed stable monthly regimen of SRL for 3 months prior to
             screening

          -  Able and willing to participate in a 53-week treatment and 14-week post-treatment
             study

        Exclusion Criteria:

          -  Treatment with any other acromegaly medications taken prior to Day 1 within the time
             period: bromocriptine: 2 weeks, carbergoline: 4 weeks, quinagolide: 4 weeks,
             pegvisomant: 4 weeks and pasireotide: 4 months

          -  Participant who received surgery for pituitary adenoma in the last 3 months prior to
             screening and participants needing and/or planning to receive surgery for the
             pituitary adenoma during the trial

          -  Unwilling to comply with required study procedures during the treatment and
             post-treatment periods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kovlac5@freemail.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>nagy@belklinika.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szeged University - Szent-Gyorgyi Albert Clinical Center - I. Belgyógyászati Klinika (Internal Medicine)</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>valkusz.zsuzsanna@med.u-szeged.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos - Endocrinology clinic</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>zilaitiene@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaidoto Urbanaviciaus Individuali imone - Endokrinologijos klinika</name>
      <address>
        <city>Vilnius</city>
        <zip>9112</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Vaidotas.Urbanavicius@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>B_Serwis Popenda Sp. J. Specjalistyczna Przychodnia Lekarsk</name>
      <address>
        <city>Chorzów</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>grazyna.med@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>beatakos@ka.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Nowoczesnych Terapii &quot;Dobry Lekarz&quot; Sp. z o. o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>grzegorz.sokolowski@dobrylekarz.com.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sól</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>halabura@twojaprzychodnia.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p.</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>napora.piotr@cbk.wroc.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Unirea - Bucuresti, Endocrinologie</name>
      <address>
        <city>Bucharest</city>
        <zip>Cod 010567</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>badicrin@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj - Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>c_e_georgescu@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta 'Pius Brinzeu' Timisoara</name>
      <address>
        <city>Timişoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>vlad.mihaela@umft.ro</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>iopascanu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multi-field Medical Clinic Anturium LLC</name>
      <address>
        <city>Barnaul</city>
        <zip>656043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>endo-akkb@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>isaeva.com@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kvitkova_lv@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Endocrinology</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jannabelaya@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov Moscow First State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mgp.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>oushab@ngs.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Endocrinology</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Hospital</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>endo-ookb@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>grineva_e@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution of the Tver Region (Regional Clinical Hospital)</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Diabet69@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sanendo1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly, IONIS-GHR-LRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

